Microbiome-derived antimicrobial peptides show therapeutic activity against the critically important priority pathogen, Acinetobacter baumannii.
Acinetobacter baumannii
/ drug effects
Microbial Sensitivity Tests
Biofilms
/ drug effects
Animals
Antimicrobial Peptides
/ pharmacology
Humans
Anti-Bacterial Agents
/ pharmacology
Drug Synergism
Moths
/ microbiology
Amoxicillin
/ pharmacology
Erythromycin
/ pharmacology
Gentamicins
/ pharmacology
Circular Dichroism
Cell Line
Antimicrobial Cationic Peptides
/ pharmacology
Acinetobacter Infections
/ drug therapy
Gene Expression Profiling
Journal
NPJ biofilms and microbiomes
ISSN: 2055-5008
Titre abrégé: NPJ Biofilms Microbiomes
Pays: United States
ID NLM: 101666944
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
received:
25
02
2024
accepted:
21
08
2024
medline:
1
10
2024
pubmed:
1
10
2024
entrez:
30
9
2024
Statut:
epublish
Résumé
Acinetobacter baumannii is designated by the World Health Organisation as a critical priority pathogen. Previously we discovered antimicrobial peptides (AMPs), namely Lynronne-1, -2 and -3, with efficacy against bacterial pathogens, such as Staphylococcus aureus and Pseudomonas aeruginosa. Here we assessed Lynronne-1, -2 and -3 structure by circular dichroism and efficacy against clinical strains of A. baumannii. All Lynronne AMPs demonstrated alpha-helical secondary structures and had antimicrobial activity towards all tested strains of A. baumannii (Minimum Inhibitory Concentrations 2-128 μg/ml), whilst also having anti-biofilm activity. Lynronne-2 and -3 demonstrated additive effects with amoxicillin and erythromycin, and synergy with gentamicin. The AMPs demonstrated little toxicity towards mammalian cell lines or Galleria mellonella. Fluorescence-based assay data demonstrated that Lynronne-1 and -3 had higher membrane-destabilising action against A. baumannii in comparison with Lynronne-2, which was corroborated by transcriptomic analysis. For the first time, we demonstrate the therapeutic activity of Lynronne AMPs against A. baumannii.
Identifiants
pubmed: 39349945
doi: 10.1038/s41522-024-00560-2
pii: 10.1038/s41522-024-00560-2
doi:
Substances chimiques
Antimicrobial Peptides
0
Anti-Bacterial Agents
0
Amoxicillin
804826J2HU
Erythromycin
63937KV33D
Gentamicins
0
Antimicrobial Cationic Peptides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
92Informations de copyright
© 2024. The Author(s).
Références
van der Kolk, J. H., Endimiani, A., Graubner, C., Gerber, V. & Perreten, V. Acinetobacter in veterinary medicine, with an emphasis on Acinetobacter baumannii. J. Glob. Antimicrob. Resist. 16, 59–71 (2019).
pubmed: 30144636
doi: 10.1016/j.jgar.2018.08.011
Heidari, H. et al. Molecular analysis of drug-resistant Acinetobacter baumannii isolates by ERIC-PCR. Meta Gene 17, 132–135 (2018).
doi: 10.1016/j.mgene.2018.06.001
Nocera, F. P., Attili, A. R. & De Martino, L. Acinetobacter baumannii: its clinical significance in human and veterinary medicine. Pathogens 10, https://doi.org/10.3390/pathogens10020127 (2021).
Nishimizu S., Shiota S., Oshiumi T., Takakura T. & Miyazaki E. A case of community-onset Acinetobacter pneumonia in a healthy person. IDCases. 24, e01133 (2021).
Liao, Y. et al Case report: acinetobacter baumannii septic arthritis in an immunocompetent infant. Front. med. 10, 1135178 (2023).
Asif, M., Alvi, I. A. & Rehman, S. U. Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect. Drug Resist. 11, 1249–1260 (2018).
pubmed: 30174448
pmcid: 6110297
doi: 10.2147/IDR.S166750
Karakonstantis, S., Ioannou, P., Samonis, G. & Kofteridis, D. P. Systematic review of antimicrobial combination options for pandrug-resistant acinetobacter baumannii. Antibiotics 10, 1344 (2021).
Pendleton, J. N., Gorman, S. P. & Gilmore, B. F. Clinical relevance of the ESKAPE pathogens. Expert Rev. Antiinfect. Ther. 11, 297–308 (2013).
doi: 10.1586/eri.13.12
WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. (World Health Organization, Geneva, 2024).
Gedefie, A. et al. Acinetobacter baumannii biofilm formation and its role in disease pathogenesis: a review. Infect. Drug Resist. 14, 3711–3719 (2021).
pubmed: 34531666
pmcid: 8439624
doi: 10.2147/IDR.S332051
Huang, C., Chen, I. & Tang, T. Colistin monotherapy versus colistin plus meropenem combination therapy for the treatment of multidrug-resistant acinetobacter baumannii infection: a meta-analysis. J. Clin. Med. 11, 3239 (2022).
Abdul-Mutakabbir, J. C. et al. In vitro antibacterial activity of cefiderocol against multidrug-resistant acinetobacter baumannii. Antimicrob. Agents Chemother. 65, e0264620 (2021).
Bartal, C., Rolston, K. V. I. & Nesher, L. Carbapenem-resistant Acinetobacter baumannii: colonization, infection and current treatment options. Infect. Dis. Ther. 11, 683–694 (2022).
pubmed: 35175509
pmcid: 8960525
doi: 10.1007/s40121-022-00597-w
Smoke, S. M. et al. Evolution and transmission of cefiderocol-resistant Acinetobacter baumannii during an outbreak in the burn intensive care unit. Clin. Infect. Dis. 76, e1261–e1265 (2022).
Mattick, A. T. R., Hirsch, A. & Berridge, N. J. Further observations on an inhibitory substance (nisin) from lactic streptococci. Lancet 250, 5–8 (1947).
doi: 10.1016/S0140-6736(47)90004-4
Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 415, 389–395 (2002).
pubmed: 11807545
doi: 10.1038/415389a
Feng, X., Sambanthamoorthy, K., Palys, T. & Paranavitana, C. The human antimicrobial peptide LL-37 and its fragments possess both antimicrobial and antibiofilm activities against multidrug-resistant Acinetobacter baumannii. Peptides 49, 131–137 (2013).
pubmed: 24071034
doi: 10.1016/j.peptides.2013.09.007
Irazazabal, L. N. et al. Fast and potent bactericidal membrane lytic activity of PaDBS1R1, a novel cationic antimicrobial peptide. Biochim. Biophys. Acta Biomembr. 1861, 178–190 (2019).
pubmed: 30463701
doi: 10.1016/j.bbamem.2018.08.001
Macia, M. D., Rojo-Molinero, E. & Oliver, A. Antimicrobial susceptibility testing in biofilm-growing bacteria. Clin. Microbiol. Infect. 20, 981–990 (2014).
pubmed: 24766583
doi: 10.1111/1469-0691.12651
Babapour, E., Haddadi, A., Mirnejad, R., Angaji, S.-A. & Amirmozafari, N. Biofilm formation in clinical isolates of nosocomial Acinetobacter baumannii and its relationship with multidrug resistance. Asian Pac. J. Trop. Biomed. 6, 528–533 (2016).
doi: 10.1016/j.apjtb.2016.04.006
Malanovic, N. & Lohner, K. Gram-positive bacterial cell envelopes: the impact on the activity of antimicrobial peptides. Biochim. Biophys. Acta 1858, 936–946 (2016).
pubmed: 26577273
doi: 10.1016/j.bbamem.2015.11.004
Yeaman, M. R. & Yount, N. Y. Mechanisms of antimicrobial peptide action and resistance. Pharm. Rev. 55, 27–55 (2003).
pubmed: 12615953
doi: 10.1124/pr.55.1.2
Prive, F. et al. Isolation and characterization of novel lipases/esterases from a bovine rumen metagenome. Appl. Microbiol. Biotechnol. 99, 5475–5485 (2015).
pubmed: 25575887
pmcid: 4464377
doi: 10.1007/s00253-014-6355-6
Oyama, L. B. et al. Buwchitin: a ruminal peptide with antimicrobial potential against enterococcus faecalis. Front. Chem. 5, 51 (2017).
pubmed: 28748180
pmcid: 5506224
doi: 10.3389/fchem.2017.00051
Mulkern, A. J. et al. Microbiome-derived antimicrobial peptides offer therapeutic solutions for the treatment of Pseudomonas aeruginosa infections. NPJ Biofilms Microbiol. 8, 70 (2022).
doi: 10.1038/s41522-022-00332-w
Oyama, L. B. et al. The rumen microbiome: an underexplored resource for novel antimicrobial discovery. NPJ Biofilms Microbiol. 3, 33 (2017).
doi: 10.1038/s41522-017-0042-1
Oyama, L. B. et al. In silico identification of two peptides with antibacterial activity against multidrug-resistant Staphylococcus aureus. NPJ Biofilms Microbiomes 8, 58 (2022).
pubmed: 35835775
pmcid: 9283466
doi: 10.1038/s41522-022-00320-0
Jayawant, E. S. et al. Molecular basis of selectivity and activity for the antimicrobial peptide lynronne-1 informs rational design of peptide with improved activity. Chembiochem 22, 2430–2439 (2021).
pubmed: 34028161
pmcid: 8362026
doi: 10.1002/cbic.202100151
Maisetta, G. et al. Evaluation of the inhibitory effects of human serum components on bactericidal activity of human beta-defensin 3. Peptides 29, 1–6 (2008).
pubmed: 18045738
doi: 10.1016/j.peptides.2007.10.013
Garcia L. Synergism testing: broth microdilution checkerboard and broth macrodilution methods. Clinical Microbiology Procedures Handbook Vol 3, (ASM Press, 2014).
Gan, B.-H., Siriwardena, T. N., Javor, S., Darbre, T. & Reymond, J.-L. Fluorescence imaging of bacterial killing by antimicrobial peptide dendrimer G3KL. ACS Infect. Dis. 5, 2164–2173 (2019).
pubmed: 31618574
doi: 10.1021/acsinfecdis.9b00299
Greenfield, N. J. Using circular dichroism spectra to estimate protein secondary structure. Nat. Protoc. 1, 2876–2890 (2006).
pubmed: 17406547
pmcid: 2728378
doi: 10.1038/nprot.2006.202
Neshani, A. et al. Antimicrobial peptides as a promising treatment option against Acinetobacter baumannii infections. Micro Pathog. 146, 104238 (2020).
doi: 10.1016/j.micpath.2020.104238
Spencer, J. J., Pitts, R. E., Pearson, R. A. & King, L. B. The effects of antimicrobial peptides WAM-1 and LL-37 on multidrug-resistant Acinetobacter baumannii. Pathog. Dis. 76, https://doi.org/10.1093/femspd/fty007 (2018).
Kragh, K. N., Alhede, M., Kvich, L. & Bjarnsholt, T. Into the well-A close look at the complex structures of a microtiter biofilm and the crystal violet assay. Biofilm 1, 100006 (2019).
pubmed: 33447793
pmcid: 7798451
doi: 10.1016/j.bioflm.2019.100006
Duplantier, A. J. & van Hoek, M. L. The human cathelicidin antimicrobial peptide ll-37 as a potential treatment for polymicrobial-infected wounds. Front. Immunol. 4, 143 (2013).
pubmed: 23840194
pmcid: 3699762
doi: 10.3389/fimmu.2013.00143
Shah, P., Hsiao, F. S., Ho, Y. H. & Chen, C. S. The proteome targets of intracellular targeting antimicrobial peptides. Proteomics 16, 1225–1237 (2016).
pubmed: 26648572
doi: 10.1002/pmic.201500380
Maron, B., Rolff, J., Friedman, J. & Hayouka, Z. Antimicrobial peptide combination can hinder resistance evolution. Microbiol. Spectr. 10, e00973–00922 (2022).
pubmed: 35862981
pmcid: 9430149
doi: 10.1128/spectrum.00973-22
Schäfer, A.-B. & Wenzel, M. A how-to guide for mode of action analysis of antimicrobial peptides. Front. Cell. Infect. Microbiol. 10, 540898 (2020).
pubmed: 33194788
pmcid: 7604286
doi: 10.3389/fcimb.2020.540898
Henry, R. et al. The transcriptomic response of Acinetobacter baumannii to colistin and doripenem alone and in combination in an in vitro pharmacokinetics/pharmacodynamics model. J. Antimicrob. Chemother. 70, 1303–1313 (2015).
pubmed: 25587995
pmcid: 4398468
doi: 10.1093/jac/dku536
Pakharukova, N. et al. Structural basis for Acinetobacter baumannii biofilm formation. Proc. Natl. Acad. Sci. USA 115, 5558–5563 (2018).
pubmed: 29735695
pmcid: 6003481
doi: 10.1073/pnas.1800961115
Iturriaga, G., Suarez, R. & Nova-Franco, B. Trehalose metabolism: from osmoprotection to signaling. Int. J. Mol. Sci. 10, 3793–3810 (2009).
pubmed: 19865519
pmcid: 2769160
doi: 10.3390/ijms10093793
Crippen, C. S., Glushka, J., Vinogradov, E. & Szymanski, C. M. Trehalose-deficient Acinetobacter baumannii exhibits reduced virulence by losing capsular polysaccharide and altering membrane integrity. Glycobiology 31, 1520–1530 (2021).
pubmed: 34473830
doi: 10.1093/glycob/cwab096
Hubloher, J. J. et al. Trehalose-6-phosphate-mediated phenotypic change in Acinetobacter baumannii. Environ. Microbiol. 22, 5156–5166 (2020).
pubmed: 32618111
doi: 10.1111/1462-2920.15148
Drlica, K., Malik, M., Kerns, R. J. & Zhao, X. Quinolone-mediated bacterial death. Antimicrob. Agents Chemother. 52, 385–392 (2008).
pubmed: 17724149
doi: 10.1128/AAC.01617-06
Fox, M. A., Thwaite, J. E., Ulaeto, D. O., Atkins, T. P. & Atkins, H. S. Design and characterization of novel hybrid antimicrobial peptides based on cecropin A, LL-37 and magainin II. Peptides 33, 197–205 (2012).
pubmed: 22289499
doi: 10.1016/j.peptides.2012.01.013
Amerikova, M., Pencheva El-Tibi, I., Maslarska, V., Bozhanov, S. & Tachkov, K. Antimicrobial activity, mechanism of action, and methods for stabilisation of defensins as new therapeutic agents. Biotechnol. Biotechnol. Equip. 33, 671–682 (2019).
doi: 10.1080/13102818.2019.1611385
Han, Y., Zhang, M., Lai, R. & Zhang, Z. Chemical modifications to increase the therapeutic potential of antimicrobial peptides. Peptides 146, 170666 (2021).
pubmed: 34600037
doi: 10.1016/j.peptides.2021.170666
Chen, C. H. & Lu, T. K. Development and challenges of antimicrobial peptides for therapeutic applications. Antibiotics 9, 24 (2020).
pubmed: 31941022
pmcid: 7168295
doi: 10.3390/antibiotics9010024
Avitabile, C., D’Andrea, L. D. & Romanelli, A. Circular Dichroism studies on the interactions of antimicrobial peptides with bacterial cells. Sci. Rep. 4, 4293 (2014).
pubmed: 24618744
pmcid: 3950807
doi: 10.1038/srep04293
Kelly, S. M., Jess, T. J. & Price, N. C. How to study proteins by circular dichroism. Biochim. Biophys. Acta 1751, 119–139 (2005).
pubmed: 16027053
doi: 10.1016/j.bbapap.2005.06.005
Reed, J. & Reed, T. A. A set of constructed type spectra for the practical estimation of peptide secondary structure from circular dichroism. Anal. Biochem. 254, 36–40 (1997).
pubmed: 9398343
doi: 10.1006/abio.1997.2355
Wiegand, I., Hilpert, K. & Hancock, R. E. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat. Protoc. 3, 163–175 (2008).
pubmed: 18274517
doi: 10.1038/nprot.2007.521
Odenholt, I., Cars, O. & Lowdin, E. Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens. J. Antimicrob. Chemother. 54, 1062–1066 (2004).
pubmed: 15563517
doi: 10.1093/jac/dkh484
Garcia, L. Synergism testing: broth microdilution checkerboard and broth macrodilution methods. Clin. Microbiol. Proced. Handb. 1, 140–162 (2010).
Hu, H. et al. Biofilm activity and sludge characteristics affected by exogenous N-acyl homoserine lactones in biofilm reactors. Bioresour. Technol. 211, 339–347 (2016).
pubmed: 27030953
doi: 10.1016/j.biortech.2016.03.068
Di Pasquale, E. et al. Biophysical studies of the interaction of squalamine and other cationic amphiphilic molecules with bacterial and eukaryotic membranes: importance of the distribution coefficient in membrane selectivity. Chem. Phys. Lipids 163, 131–140 (2010).
pubmed: 19883637
doi: 10.1016/j.chemphyslip.2009.10.006
Casanova, M. et al. Evaluation of the efficiency of random and diblock methacrylate-based amphiphilic cationic polymers against major bacterial pathogens associated with cystic fibrosis. Antibiotics 12, 120 (2023).
Haudecoeur, R. et al. 2-hydroxypyridine-N-oxide-embedded aurones as potent human tyrosinase inhibitors. ACS Med. Chem. Lett. 8, 55–60 (2017).
pubmed: 28105275
doi: 10.1021/acsmedchemlett.6b00369
Olleik, H. et al. Comparative structure-activity analysis of the antimicrobial activity, cytotoxicity, and mechanism of action of the fungal cyclohexadepsipeptides enniatins and beauvericin. Toxins 11, 514 (2019).
Kay, S., Edwards, J., Brown, J. & Dixon, R. Galleria mellonella infection model identifies both high and low lethality of clostridium perfringens toxigenic strains and their response to antimicrobials. Front. Microbiol. 10, 1281 (2019).
pubmed: 31333591
pmcid: 6616247
doi: 10.3389/fmicb.2019.01281